Real-World Treatment Patterns and Clinical Response Among US Patients with C3 Glomerulopathy (C3G) Receiving Iptacopan: APPRISE-C3G Data Platform (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0854; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Conclusion Tx-experienced patients with C3G receiving iptacopan demonstrated high tx adherence; data trended toward early proteinuria improvement with iptacopan in routine practice. Enrollment is ongoing and additional data will be available in the near future."
Clinical • HEOR • Real-world • Real-world evidence • Complement-mediated Rare Disorders • Glomerulonephritis • Nephrology • Renal Disease
|
|
Mohanram Narayanan; Briana C. Ndife; Helen Trenz; Anirban Bose; Neema Stephens; Claire Buchan; Tayler Buchan; Eugene Baraka; Peter Gargano; Pietro A. Canetta
|